Archive for the ‘Media Control’ Category

Gesture Control Interfaces Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2022 | Key Players: GestureTek, Gestigon, Leap…

This new research report compilation added as an assessment overview of the global Gesture Control Interfaces market is directed to unravel crucial details about market developments, encompassing various factors such as market trends, lingering barrier implications as well as dominant drivers that effectively carve a favorable growth route for global Gesture Control Interfaces market progression and growth. The report specifically underpins superlative reader comprehension about multiple market developments by gauging into regional growth spots.

Access the PDF sample of the Gesture Control Interfaces Market report @ https://www.orbisresearch.com/contacts/request-sample/3059735?utm_source=Atish

Key Players Mentioned in the Report:

GestureTekGestigonLeap GestureEyeSight TechnologiesThalmic LabsIntelApple4tiitooLogbarPointGrabNimble VRApotact LabsArcSoft

A keen observation and evaluation of the Gesture Control Interfaces market developments based on qualitative and quantitative research practices have been meticulously compiled to understand dynamics such as drivers, restraints, challenges and threats that closely influence holistic growth in global Gesture Control Interfaces market.

Make an enquiry of Gesture Control Interfaces Market report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/3059735?utm_source=Atish

Some of the most crucial market relevant information drawn in the report is aimed at equipping market players with a crisp overview of fast transitioning vendor landscape. The report is also designed to influence lucrative decision making amongst prominent players in terms of their investment discretion towards most appropriate investment decisions pertaining to dynamic product and pricing mix to initiate user acceptance. A close review of the sub-segmentation has also been tagged in the report, aimed at unveiling novel growth opportunities, offsetting market saturation. Minute classification of the growth hubs, encompassing details on global and local developments alike to entice critical decision making.

Types Covered in Report:(Wearable Based, Vision Based, Infrared Based, Electric Field Based, Ultrasonic Based)

Application Covered in Report:(Consumer Electronics, Automotive, Gaming and Entertainment, Healthcare, Defense)

Browse the complete Gesture Control Interfaces Market report @ https://www.orbisresearch.com/reports/index/global-gesture-control-interfaces-market-report-2019?utm_source=Atish

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 515

Link:
Gesture Control Interfaces Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2022 | Key Players: GestureTek, Gestigon, Leap...

War of the weedkiller: why environmentalists are concerned about moves to ban Roundup – The Guardian

Glyphosate the weedkiller better known by its most-famous brand name Roundup does not have the best of public profiles.

The subject of multibillion dollar payouts over claims it causes cancer, the worlds most-popular herbicide developed by Monsanto is not known for having too many friends among environmentalists.

But away from lawsuits and petitions, there are concerns among some opponents of Australias invasive weeds that glyphosate a key tool in their armoury could be taken away from them.

Next week the Invasive Species Council will begin posting and emailing copies of a new report that looks to defend the chemical from what the council fears is a trend towards restricting its use, and even banning it entirely.

A ban on glyphosate would have serious environmental consequences, says the report, seen by Guardian Australia.

Weed invasions would increase in areas of native vegetation including national parks, and erosion would increase on farms.

A small number of Australian councils such as Georges River in south Sydney and Fairfield in the citys west have already banned glyphosate. So have several countries.

In July 2019, 500 staff at Blacktown city council walked off the job in protest at being ordered to use glyphosate. They returned when the council promised to trial alternatives.

Andrew Cox, the Invasive Species Councils chief executive, fears that the steady flow of opposition could lead to a flood.

Were worried that restrictions are being put in place across Australia without a scientific basis, he says.

We want to make sure that chemical use is safe and necessary, and we dont want to put peoples lives at risk. But we dont want to make it impossible for people to do really important weed control.

Weeds are a major threat to biodiversity and without active management to control weeds and stop them spreading, it would threaten our ecosystems.

Glyphosate is a good herbicide that has lots of benefits to weed control, particularly for environmental restoration projects and land care programs. To not have that tool available will severely hamper those efforts.

The Invasive Species Councils report is researched and written by Tim Low, an ecologist and author of seven books.

He says such was the chemicals reputation, just authoring the report was the riskiest thing I have ever written.

But he says he has become worried the chemical was being unfairly maligned in the public eye, as well as in the left-leaning media.

Lows report picks through the scientific research on the chemical, its origins, uses and its criticisms.

Low also charts the herbicides recent history, including the fallout from a 2015 declaration by the World Health Organisations International Agency for Research on Cancer (IARC) that glyphosate was a probably carcinogenic.

The decision to add glyphosate to the agencys 2A category, puts it alongside other chemicals that are probable carcinogens, but also alongside other activities in the same category such as consumption of red meat, doing night shifts, working in a hairdresser and drinking beverages hotter than 65C.

The IARCs category of known carcinogens includes alcohol, processed meat and solar radiation (sunshine).

Legitimate concerns about glyphosate, writes Low, have been exacerbated by some wildly exaggerated comments.

Low writes: Cancer is such a feared disease that many people might suppose that any cancer risk is reason to ban a chemical. But todays world abounds in carcinogens.

The governments Australian Pesticides and Veterinary Medicines Authority carried out an assessment of glyphosate after the IARC listing. About 500 products containing glyphosate are registered for use in Australia.

The agency said after the assessment it would monitor emerging science closely, but concluded there are no scientific grounds for placing glyphosate and products containing glyphosate under formal reconsideration. It said the weight of evidence showed exposure to glyphosate does not pose a carcinogenic or genotoxic risk to humans.

The agency is not alone in pushing back against the IARCs finding. A review from the United States governments EPA found there are no risks of concern to human health when glyphosate is used in accordance with its current label.

The EUs European Chemicals Agency also found no reason to classify glyphosate as a carcinogen, although it could cause eye damage and was toxic to aquatic life.

But the chemical continues to make headlines and have strong and passionate opposition, and court hearings are on the horizon.

Monsanto developed the weedkiller in the 1970s. In the 1990s, Monsanto developed genetically-modified crops that were Roundup ready and resistant to the herbicide.

In August 2018, Monsanto was ordered to pay US$289m ($397m) to a groundskeeper dying of blood cell cancer. Bayer, Monsantos owner, is appealing that case, and two others.

In June this year, the German multinational Bayer announced it would be paying almost $16bn to settle claims the firm inherited when it bought Monsanto in 2018.

Bayer chief executive Werner Baumann said at the time there was extensive scientific evidence that the companys glyphosate-based herbicide Roundup does not cause cancer and the company stood strongly behind its glyphosate-based products.

A class action is also being brought in Australia against three former and current Monsanto companies, slated for a hearing in federal court in March 2022.

Lawyers allege Roundup is carcinogenic and raises peoples risk of the blood cancer non-Hodgkin lymphoma.

Jane Bremmer, a campaigner at the National Toxics Network, said glyphosate was prolific in the environment, dangerous, and court cases around the world had shown the herbicide was carcinogenic.

I dont know how that evidence can be ignored, she says. Its an absolute delusion to suggest that you can only control weeds with poison.

Glyphosate is leaving a toxic load in our groundwater and river systems.

Bremmer is a volunteer with a group caring for a bush reserve on the Swann River on Perths outskirts without the use of chemicals. They prevent weeds growing by using organic products, covering areas to block sunlight and mechanical and hand weeding, she says.

Glyphosate and other chemicals are poorly regulated because of the power of the petrochemical industry, she says.

Peter Dixon is a board member of the Australian Association of Bush Regenerators (AABR) a group with more than 700 members promoting ecological restoration.

He says they are a pragmatic bunch of people who know their way around the differences between a hazard (like a shark) and a risk (the chance of being bitten).

We all have chemicals in our houses that can kill us, but we mitigate the risk of those hazards through knowledge and processes. Its the same with herbicides, he says.

According to Dixon, the groups members are not worried about getting cancer, but they are worried about moves to ban glyphosate.

Dixon, an environmental consultant and volunteer bush regenerator, has been part of an AABR working group on glyphosate created to try and counter misinformation over the herbicide.

On the banks of the degraded Duck River in greater Sydney, Dixon has used the herbicide for years as part of a volunteer bush care group to knock back invasive balloon vine and trad.

Bush regenerators use the herbicide as a spray and also on woody weeds where the plant is cut back and the chemical applied like paint on to the stump.

He describes glyphosate as a critical tool that can keep invasive weeds at bay on a scale that mechanical measures could not.

He says in bush regeneration, glyphosate is used not as a perennial treatment like in food production but in a way that lets native vegetation come back to the point where the chemical isnt needed any more.

Other available chemicals, he says, have not been as well studied as glyphosate and could turn out to be more toxic or less effective.

The amount of funding that goes into restoring ecosystems is tiny, says Dixon.

Its possible that without the herbicide glyphosate you would need an order of magnitude more resources to do that work.

Because of the rate of land clearing and degradation, we cant afford that luxury.

Read the rest here:
War of the weedkiller: why environmentalists are concerned about moves to ban Roundup - The Guardian

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for…

First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,and a Confirmed Partial Response

Updated Interim Data from Ongoing Phase 1 Study of Controlled IL-12 in Combination with Nivolumab Show a mOS of 16.9 Months in PatientsReceiving 10 mg Veledimex

First Data from Ongoing Phase 1/2 study of Controlled IL-12 Monotherapy Demonstrate Promising Safety Profile in Patient with DIPG

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP) today announced the presentation of new clinical data from three ongoing trials of Ad-RTS-hIL-12 plus veledimex (Controlled IL-12) for the treatment of recurrent glioblastoma (rGBM) and diffuse intrinsic pontine glioma (DIPG) at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting. Data highlights include the first discussion of interim data from the phase 2 study of Controlled IL-12 in combination with cemiplimab for the treatment of rGBM that has recently completed enrollment, updated interim data from the phase 1 study of Controlled IL-12 in combination with nivolumab for the treatment of rGBM and data from the first patient enrolled in the ongoing phase 1/2 study of Controlled IL-12 monotherapy for the treatment of DIPG.

Glioblastoma is a highly aggressive tumor and despite advances in oncology over the last few decades, median overall survival for patients with progressive GBM remains less than one year, said Rimas Lukas, M.D., Associate Professor of Neurology at Northwestern Memorial Hospital Malnati Brain Tumor Institute and investigator on the phase 2 trial of Controlled IL-12 in combination with cemiplimab. Here we report data for the first time from the ongoing phase 2 study of Controlled IL-12 in combination with PD-1 inhibitor cemiplimab, showing activation of the immune system across patients. These data are highly encouraging and underscore the potential of Controlled IL-12 to transform the treatment landscape of recurrent glioblastoma.

The updated data on combining Controlled IL-12 with nivolumab reveal a subset of patients with rGBM that demonstrate very encouraging survival at 16 months. This observation reveals that immune modulation with IL-12 and anti-PD-1 is well tolerated with an apparent survival benefit that will need further confirmation in upcoming more advanced clinical trials. These survival data in conjunction with previously reported MRIs showing partial responses is consistent with immune-mediated anti-tumor effects, noted E. Antonio Chiocca, M.D., Ph.D., study investigator, Chairman of Neurosurgery at Brigham and Women's Hospital, Professor of Neurosurgery at Harvard Medical School, and Surgical Director of the Center for Neuro-oncology at Dana-Farber Cancer Institute.

Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, added, As we reflect on the growing body of evidence across our efforts utilizing our Controlled IL-12 platform, we are encouraged by the signs of efficacy we are seeing in these very hard-to-treat cancers. Not only are we observing cytokine production, increases in intra-tumoral T cells (cold tumors turning hot), and predictable safety after treatment with Controlled IL-12 as a monotherapy and in combination with PD-1 inhibitors, but we have reported at least one partial response in each rGBM trial we have conducted to date, for a total of six. These MRI data, along with IL-12-driven immune response complement our encouraging survival data and we look forward to future data read-outs in 2021. Further, the initial look at data from the first patient in our phase 1/2 pediatric glioma study supports Controlled IL-12s safety profile and continued development.

Controlled IL-12 in combination with PD-1 inhibitor cemiplimab is currently being examined in a phase 2 study for the treatment rGBM (NCT04006119). Preliminary data highlights shared in an on-demand presentation titled Phase 2 Trial of Controlled IL-12 in Combination with PD-1 Inhibitor in Adult Subjects with Recurrent Glioblastoma (Abstract #901183) and presented by Dr. Lukas, include:

Controlled IL-12 in combination with the PD-1 inhibitor nivolumab is currently being examined in a phase 1 study for the treatment of rGBM (NCT03636477). Interim data highlights shared in an oral on-demand presentation titled Combination of Controlled Interleukin-12 Gene Therapy with Immune Checkpoint Blockade in Recurrent Glioblastoma: Updated Results of a Multi-Institutional, Open Label Phase 1 Trial (Abstract #901050) and presented by Dr. Chiocca include:

As a follow up to our prior readout (ASCO 2020) for this combination which reported partial responses by MRI, the two patients had meaningful improvements in survival with one patient on 20 mg veledimex surviving 17.4 months (now deceased) and the other (10 mg veledimex) surviving 21.0 months (in follow up).

Controlled IL-12 monotherapy is being studied in a phase 1/2 dose escalation study (NCT03330197) for the treatment of children with gliomas, including DIPG. Data highlights from the first patient in the study shared in a poster discussion titled Phase I/II Study of Controlled IL-12 as Immunotherapy for Diffuse Intrinsic Pontine Glioma (DIPG) (Abstract #901123) and presented by Stewart Goldman, M.D., Division Head Hematology-Oncology, Neuro-Oncology & Stem Cell Transplantation at Lurie Children's Hospital and investigator in the study, include:

It is important to note that these trials, including our previously disclosed monotherapy study now consist of over 125 patients with rGBM. These provide deep learning that is ongoing and is part of the efforts to develop Controlled IL-12 as a potential therapy for brain cancers. We will continue to monitor the data across both the monotherapy and checkpoint inhibitor combination studies in the coming months. We believe there are multiple potential paths to registration for our Controlled IL-12 program, either as a monotherapy therapy or in combination with other agents, concluded Dr. Cooper.

More information about Controlled IL-12 is available on the Companys website at https://ziopharm.com/controlled-il-12/. Additionally, the presentations presented at the SNO 2020 Virtual Meeting will be available on the Companys website in the Scientific and Medical Publications section.

AboutZiopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand others. For more information, please visitwww.ziopharm.com.

Forward-Looking Statements DisclaimerThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's business and strategic plans and the progress and timing of the Company's research and development programs, including the anticipated dates for the readouts of its clinical trials and the Companys expectations regarding future enrollment in its clinical trials. Although Ziopharms management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharms product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharms intellectual property rights; and competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharms Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Investor Relations Contacts:Adam D. Levy, PhD, MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E: alevy@ziopharm.com

Chris TaylorVP, IR and Corporate CommunicationsT: 617.502.1881E: ctaylor@ziopharm.com

Media Relations Contact:LifeSci Communications:Patrick BurseyT: 646.876.4932E: pbursey@lifescicomms.com

Read more from the original source:
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for...

Its the End of an Era for the Media, No Matter Who Wins the Election – The New York Times

Many media organizations have spent the past four years generally failing to adapt to a campaign, a president, a White House and an administration that is extremely online, said Stacy-Marie Ishmael, the editorial director of the nonprofit Texas Tribune. We are only, four years in, getting to grips with how to contend with rhetorical techniques, messaging and communications steeped in misinformation and propaganda.

Others predicted a deeper cultural shift from Stephen Colberts biting satire back to the sillier Jimmy Fallon, from politics back to entertainment, whenever the studios can get production running again. But some veterans of the business of politics doubt that news coverage can really calm down or that consumers can look away.

If Biden is elected, conservatives will be energized, not retreating, said Eric Nelson, the editorial director of Broadside Books, HarperCollinss conservative imprint. Trump will keep tweeting, and new scandals from his presidency will keep unfolding for well into 2022. By the time that all chaos and nonsense runs out, Trump could be running again for 2024.

You arent the only one just barely hanging on until Election Day. Most of the top leaders of many name-brand American news institutions will probably be gone soon, too. The executive editor of The Los Angeles Times, Norm Pearlstine, is looking to recruit a successor by the end of the year, he told me. Martin Baron, the executive editor of The Washington Post, just bought a house out of town and two Posties said they expected him to depart next year. He hasnt given notice, The Posts spokeswoman, Kristine Coratti Kelly, said. And the executive editor of The New York Times, Dean Baquet, is on track to retire by the time he turns 66 in 2022, two Times executives told me, dampening speculation that he might stay longer.

Over in big TV, Mr. Zucker, of CNN, has signaled that hes frustrated with WarnerMedia, and broadcast television is overflowing with speculation about how long the network news chiefs will stay on, though no executives have suggested imminent departures. Everyone is assuming theres going to be turnover everywhere, and everyone is absolutely terrified about who is going to come in, one television industry insider said.

This isnt just the usual revolving door. Newsroom leaders face strong pulls in conflicting directions. Outlets all along the spectrum, from the staid BBC to the radical Intercept, have been moving to reassert final editorial control over their journalists. But newsroom employees like a generation of workers across many industries are arriving with heightened demands to be given more of a say in running their companies than in years past. New leaders may find opportunities to resolve some of the heated newsroom battles of the last year, or they may walk into firestorms.

Mr. Pearlstine, the only one talking openly of his departure, told me that the new metrics for success might be different as well issues such as inclusiveness, such as being anti-racist, such as really commanding some new platform, be it podcasts or video or newsletters, in addition to having journalistic credentials.

Read more:
Its the End of an Era for the Media, No Matter Who Wins the Election - The New York Times

No Matter Who Wins the Election, Social Media Will Lose – Governing

This week the seemingly interminable 2020 presidential campaign will (hopefully) be at an end. While it is too soon to predict whether Trump or Biden will prevail on November 3, it is almost certain thatsocialmediawill be declared the undisputed loser.

If Biden wins, the Republicans will likely allegeunfair treatment onsocialmediaas a contributing factor in their loss. In the months leading up to the election,socialmediaplatforms including Facebook and Twitter have repeatedly flagged, fact-checked, or removed a number ofTrumps posts. They will blamesocialmediafor not doing more to bepolitically neutral.

If Trump wins, the Democrats will likely allege insufficientcontrol of misinformationonsocialmediaas a primary cause.False informationabout coronavirus, candidates, and conspiracies spread faster thansocialmediasites can take it down. Thus, the Democrats will blamesocialmediafor not doing more to address misinformation.

Regardless of the outcome, the losing side will be primed to blamesocialmediafor their loss and try to punish them for it over the next four years. Meanwhile, the winning side will likely say they won in spite of a brokensocialmediaenvironment and try to fix the rules to their advantage for the next election cycle.

This hostility will set the stage for Congress and the next administration to come out guns blazing to try to set new rules forsocialmedia, and such proposals may find bipartisan appeal. Some will call to break up Big Tech based on the mistaken belief that having more and smaller platforms will lead to better national dialogues. Others will demand thatsocialmediacompanies be stripped of theirliability protectionfor third-party content, unless they adhere to new rules on content moderationrules that would differ by the party in power.

Overall, the impact of such rules would be a major setback for Americans. Whensocialmediaplatforms are turned into political punching bags, they are forced to prioritize the demands of the prevailing political winds rather than the need of their users. In this case, they would likely be forced to significantly limit what the average user posts online to avoid potential violations.

While this might indeed reduce misinformation and punish those perceived as insufficiently politically neutral, it would come at the expense of the vibrancy that makes these platforms attractive to users in the first place. Moreover, it would undermine long-held values on both sides. Conservatives would be turning on their commitments to free markets and individual liberty in favor of increased regulation and government control. And by placing greater restrictions onsocialmediaplatforms, liberals would be curtailing free speech online, which would be unfortunate because, as the ACLUs national legal director David Coleexplains, the targets of censorship are typically dissidents, outsiders, the marginalized.

Win or lose, both parties are likely to targetsocialmediafollowing the 2020elections. Reactionary policies to right perceived wrongs will ultimately hurt major U.S. tech companies, reduce U.S. competitiveness, and hurt U.S. consumers. The questions about fairly and transparently moderating online content that have emerged throughout this election cycle should continue after the votes are counted, but with an eye toward improving consumer welfare, not just the next election.

This article was originally published onInformation Technology & Innovation Foundation's website.Governing's opinion columns reflect the views of their authors and not necessarily those of Governing editors or management.

See the original post:
No Matter Who Wins the Election, Social Media Will Lose - Governing